A carregar...
ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS
Survival benefit of bevacizumab (BEV) could not be confirmed for recurrent glioblastomas in EORTC 26101, while BEV is commonly chosen at recurrence due to its positive effect in daily life. BEV is usually repeated until tumor progression or adverse events, but the benefit of continuation of BEV is n...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216360/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.070 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|